The Gibco CTS Rotea Counterflow Centrifugation System has been selected as a finalist for the Edison Awards in the Technology and Tools category, honoring excellence in new product and service development and innovation.
Gibco CTS Rotea wins 2021 R&D 100 Award
Established in 1963, the R&D 100 Awards is the only S&T (science and technology) awards competition that recognizes new commercial products, technologies and materials for their technological significance that are available for sale or license. The R&D 100 Awards have long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology.
Gibco CTS Rotea wins Two Good Design Awards for design excellence
‘Gibco CTS Rotea Counterflow Centrifugation System for cell and gene therapy manufacture’ Recognised in Australia’s International Good Design Awards for Design Excellence.
The winners of Australia’s peak international design awards were announced today during the 2021 Good Design Awards Week. The Good Design Awards are the highest honour for design and innovation in the country and reward projects across 12 design disciplines and 30 subcategories.
Gibco CTS Rotea Counterflow Centrifugation System for cell and gene therapy manufacture received two prestigious Good Design Award Winner Accolades in the Product Design and Engineering Design categories in recognition for outstanding design and innovation.
The Australian Good Design Awards is the country’s oldest and most prestigious international awards for design and innovation with a proud history dating back to 1958. The Awards celebrate the best new products and services on the Australian and international market, excellence in architectural design, precinct design, engineering, fashion, digital and communication design, and reward new and emerging areas of design including design strategy, social impact design, design research and up-and-coming design talent in the Next Gen category.
The 2021 Good Design Awards attracted a record number of submissions with 933 design projects evaluated by more than 70 Australian and international Jurors, including designers, engineers, architects and thought leaders. Each entry was evaluated according to a strict set of design evaluation criteria which includes good design, design innovation and design impact. Projects recognised with an Australian Good Design Award demonstrate excellence in professional design and highlight the impact a design-led approach has on business success and social and environmental outcomes.
The Good Design Awards Jury commented:
“The functionality can be well appreciated. By integrating multiple processes into one device, this is an innovative approach to increasing the affordability of cell and gene therapies. The capacity to conduct small batch processing, higher flow rate and the high recovery aspect are strong features. It's a complex product, well designed to improve usability. Overall, a standout project that ticks all the boxes for good design in this category.”
“This is a good system that brings efficiencies to the gene therapy sector. The system is well designed and complies with global standards to allow for access to international markets. There are safety features designed into the product. The rigorous design and testing programs, together with success in gaining Early Adopter Program users, vouch for the new and valuable contribution this design makes.”
Dr. Brandon Gien, CEO of Good Design Australia said: “Receiving an Australian Good Design Award is testament to embedding design excellence at the heart of a product, service, place or experience. Although 2021 continues to be another challenging year, it is incredibly inspiring to see designers and businesses working together to find innovative, customer-centric design solutions to local and global challenges and to see them recognised and rewarded for their efforts through these prestigious Awards.”
“The importance of embracing good design principles is now more important than ever as many businesses around the world have had to completely re-think their business strategies to remain competitive. The standard of design excellence represented in this year’s Awards is the best I’ve ever seen in my 25 years of running these Awards, an encouraging sign that the design sector is flourishing,” Dr. Gien went on to say.
Gibco CTS Rotea Counterflow Centrifugation System a Finalist for 2021 R&D 100 Awards
Finalists for the 2021 R&D 100 Awards have been announced by R&D World magazine. This renowned worldwide competition, now in its 59th year, received entries from 17 different countries/regions. The Gibco CTS Rotea Counterflow Centrifugation System has been selected as a finalist in the Analytical/Test category.
PI to manufacture Scinogy’s new cell processing system for cell therapy manufacture
Planet Innovation is partnering with Melbourne-based start-up Scinogy to manufacture a revolutionary new cell processing system that is being commercialized by global biotechnology company Thermo Fisher Scientific.
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
It is amazing to finally see the Gibco CTS Rotea launched by Thermo Fisher Scientific. I want to take this opportunity to thank all of the individuals and companies that put their faith in Scinogy and helped turn our vision for cell therapy manufacturing into reality.
Training to meet demand in growing cell therapy industry
Thermo Fisher Scientific and Scinogy partner to accelerate cell and gene therapy commercialization
Thermo Fisher's collaboration with Scinogy will provide closed, modular, automated systems designed to enable scalable, cost-effective cell and gene therapy development and manufacturing.
ROTEA showcased at CCRM Australia event
It is fantastic to see the Victorian Government support the cell therapy and regenerative medicine industry through its support of CCRM Australia.
Melbourne innovation set to revolutionize cell therapy industry
A world-leading Melbourne innovation is rapidly changing the way cell therapies are manufactured to treat diseases including stroke and cerebral palsy, taking these treatments out of the lab and into hospitals.
The new cell-processing technology, ROTEA, developed by Melbourne start-up, Scinogy in conjunction with Hudson Institute of Medical Research, is significantly reducing the costs and labour associated with manufacturing cells for clinical use.
“This is game changer for the health and cell therapies sectors. The technology significantly reduces manufacturing costs, and our hope is that it means more patients can access the benefits of cell therapies,” said Scinogy CEO, David James.